Inhibrx Biosciences (INBX) Revenue (2023 - 2025)

Inhibrx Biosciences (INBX) has reported Revenue for 3 consecutive years, with $1.3 million the latest figure, recorded in Q2 2025.

• In Q2 2025, Revenue rose 1200.0% year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $1.4 million (down 23.66% YoY), while the FY2025 annual figure was $1.3 million, up 550.0% from the prior year.
• Revenue climbed to $1.3 million in Q2 2025 per INBX's latest filing, from $100000.0 in the prior quarter.
• Across five years, Revenue topped out at $1.6 million in Q4 2023 and bottomed at $30000.0 in Q2 2023.
• Historically, Revenue has averaged $547166.7 across 3 years, with a median of $109500.0 in 2023.
• Annual changes were most pronounced in 2024 — Revenue sank 93.88% — and 2025, when it surged 1200.0%.
• Inhibrx Biosciences' Revenue stood at $1.6 million in 2023, then tumbled by 93.88% to $100000.0 in 2024, then soared by 1200.0% to $1.3 million in 2025.
• Business Quant data shows INBX's Revenue at $1.3 million in Q2 2025, $100000.0 in Q4 2024, and $100000.0 in Q2 2024.